drugset / Trial / NCT04522895
IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT
Phase 2
Completed
50 enrolled
Heinrich-Heine University, Duesseldorf
Celgene Corporation · collabKoordinierungszentrum für Klinische Studien Düsseldorf · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML and AML in remission after allo-SCT.
Timeline
- Start
- 2020-08-27
- Primary completion
- 2024-07-24
- Completion
- 2024-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enasidenib | Small molecule | 100 mg | — |